Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Beijing FDA Speeds Up its Fast-Track Review

publication date: Jan 31, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
To promote the research and registration of innovative therapeutics in Beijing, the Beijing FDA has issued a new set of guidelines for fast-track status, effective February 12, 2012. The new set of rules mandate a review time of just 15 working days, down from 30 working days under the previous guidelines. Also, seven categories of drugs now qualify for fast-track status in Beijing, against four categories of eligible candidates in the national-level SFDA. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...